IGC Pharma, Inc. (IGC) Institutional Ownership

Ownership Summary

The institutional landscape for IGC Pharma, Inc. (NYSE:IGC) includes 29 filers as of the latest reporting cycle ending December 2025.

• These investors collectively held 5.3% of the company's total shares outstanding in December 2025, down from 5.9% in September 2025.
• Quarterly data indicates a -6.19% shift in institutional share volume, and the annual owner count reflects a decrease of 3.33%.
• During the quarter, 10 institutions bought more IGC Pharma shares, 4 sold shares, and 15 of the 29 total investors held their position steady.
• The total number of shares held by institutions in IGC Pharma decreased to 4.83Mn as of December 2025, a net change of down by 318.74K shares quarter on quarter, and up 1.99Mn shares year over year.
• With 1.15Mn shares, VANGUARD GROUP INC commands the largest institutional position in IGC Pharma as of December 31, 2025, equating to 1.26% of the company.
• Among the most significant buyers of IGC Pharma during December 2025 were SUSQUEHANNA INTERNATIONAL GROUP, LLP (141.00K), LAWOOD & CO (75.00K), STATE STREET CORP (40.59K), XTX Topco Ltd (28.32K), T3 Companies, LLC (20.00K).
• Leading sellers of IGC Pharma stock in December 2025 included CITADEL ADVISORS LLC (350.25K), RENAISSANCE TECHNOLOGIES LLC (299.32K), BANK OF AMERICA CORP /DE/ (2.15K), COMMONWEALTH EQUITY SERVICES, LLC (1.60K).
• The top 10 institutional holders of IGC Pharma for the quarter ending December 2025 included VANGUARD GROUP INC (1.15Mn), RENAISSANCE TECHNOLOGIES LLC (919.64K), GEODE CAPITAL MANAGEMENT, LLC (860.48K), BlackRock, Inc. (703.80K), CITADEL ADVISORS LLC (277.59K), STATE STREET CORP (200.80K), SUSQUEHANNA INTERNATIONAL GROUP, LLP (154.96K), NORTHERN TRUST CORP (113.41K), DEARBORN PARTNERS LLC (84.40K), LAWOOD & CO (75.00K).